Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells

Creative Commons License

Reyes C. M., Teller S., Muckenhuber A., Konukiewitz B., Safak O., Weichert W., ...Daha Fazla

CLINICAL CANCER RESEARCH, cilt.26, sa.1, ss.220-231, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1158/1078-0432.ccr-19-1864
  • Dergi Adı: CLINICAL CANCER RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, Agricultural & Environmental Science Database, BIOSIS, Biotechnology Research Abstracts, EMBASE, Gender Studies Database, MEDLINE
  • Sayfa Sayıları: ss.220-231
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Purpose: Neoadjuvant therapy (neoTx) has dramatically improved the prognosis of patients with locally advanced and borderline resectable pancreatic ductal adenocarcinoma, yet its mechanisms of action on tumor cells and the tumor microenvironment are still unknown. Here, we aimed to characterize the multiple facets of neoTx-induced alterations in the pancreatic cancer microenvironment.